199 related articles for article (PubMed ID: 21922503)
1. On the selectivity and efficacy of defense peptides with respect to cancer cells.
Harris F; Dennison SR; Singh J; Phoenix DA
Med Res Rev; 2013 Jan; 33(1):190-234. PubMed ID: 21922503
[TBL] [Abstract][Full Text] [Related]
2. Structural determinants of host defense peptides for antimicrobial activity and target cell selectivity.
Takahashi D; Shukla SK; Prakash O; Zhang G
Biochimie; 2010 Sep; 92(9):1236-41. PubMed ID: 20188791
[TBL] [Abstract][Full Text] [Related]
3. Anticancer alpha-helical peptides and structure/function relationships underpinning their interactions with tumour cell membranes.
Dennison SR; Whittaker M; Harris F; Phoenix DA
Curr Protein Pept Sci; 2006 Dec; 7(6):487-99. PubMed ID: 17168782
[TBL] [Abstract][Full Text] [Related]
4. Mode of action of anticancer peptides (ACPs) from amphibian origin.
Oelkrug C; Hartke M; Schubert A
Anticancer Res; 2015 Feb; 35(2):635-43. PubMed ID: 25667440
[TBL] [Abstract][Full Text] [Related]
5. The study of single anticancer peptides interacting with HeLa cell membranes by single molecule force spectroscopy.
Shan Y; Huang J; Tan J; Gao G; Liu S; Wang H; Chen Y
Nanoscale; 2012 Feb; 4(4):1283-6. PubMed ID: 22215262
[TBL] [Abstract][Full Text] [Related]
6. From a pro-apoptotic peptide to a lytic peptide: One single residue mutation.
Zhou XR; Zhang Q; Tian XB; Cao YM; Liu ZQ; Fan R; Ding XF; Zhu Z; Chen L; Luo SZ
Biochim Biophys Acta; 2016 Aug; 1858(8):1914-25. PubMed ID: 27207743
[TBL] [Abstract][Full Text] [Related]
7. Anticancer versus antigrowth activities of three analogs of the growth-inhibitory peptide: relevance to physicochemical properties.
Mizejewski GJ; Eisele L; Maccoll R
Anticancer Res; 2006; 26(4B):3071-6. PubMed ID: 16886636
[TBL] [Abstract][Full Text] [Related]
8. A theoretical analysis of secondary structural characteristics of anticancer peptides.
Dennison SR; Harris F; Bhatt T; Singh J; Phoenix DA
Mol Cell Biochem; 2010 Jan; 333(1-2):129-35. PubMed ID: 19629645
[TBL] [Abstract][Full Text] [Related]
9. The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells.
Yang N; Strøm MB; Mekonnen SM; Svendsen JS; Rekdal O
J Pept Sci; 2004 Jan; 10(1):37-46. PubMed ID: 14959890
[TBL] [Abstract][Full Text] [Related]
10. Comparison of patient-derived high and low phosphatidylserine-exposing colorectal carcinoma cells in their interaction with anti-cancer peptides.
Wilms D; Andrä J
J Pept Sci; 2017 Jan; 23(1):56-67. PubMed ID: 28066958
[TBL] [Abstract][Full Text] [Related]
11. Structural determinants for the membrane interaction of novel bioactive undecapeptides derived from gaegurin 5.
Won HS; Seo MD; Jung SJ; Lee SJ; Kang SJ; Son WS; Kim HJ; Park TK; Park SJ; Lee BJ
J Med Chem; 2006 Aug; 49(16):4886-95. PubMed ID: 16884301
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of amphiphilic alpha-helical model peptides with systematically varied hydrophobic-hydrophilic balance and their interaction with lipid- and bio-membranes.
Kiyota T; Lee S; Sugihara G
Biochemistry; 1996 Oct; 35(40):13196-204. PubMed ID: 8855958
[TBL] [Abstract][Full Text] [Related]
13. Alpha-helical cationic anticancer peptides: a promising candidate for novel anticancer drugs.
Huang Y; Feng Q; Yan Q; Hao X; Chen Y
Mini Rev Med Chem; 2015; 15(1):73-81. PubMed ID: 25382016
[TBL] [Abstract][Full Text] [Related]
14. Effects of Pro --> peptoid residue substitution on cell selectivity and mechanism of antibacterial action of tritrpticin-amide antimicrobial peptide.
Zhu WL; Lan H; Park Y; Yang ST; Kim JI; Park IS; You HJ; Lee JS; Park YS; Kim Y; Hahm KS; Shin SY
Biochemistry; 2006 Oct; 45(43):13007-17. PubMed ID: 17059217
[TBL] [Abstract][Full Text] [Related]
15. Release of hydrophobic anticancer drug from a newly designed self-assembling peptide.
Wu M; Ye Z; Liu Y; Liu B; Zhao X
Mol Biosyst; 2011 Jun; 7(6):2040-7. PubMed ID: 21491031
[TBL] [Abstract][Full Text] [Related]
16. Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework.
Huang YB; Wang XF; Wang HY; Liu Y; Chen Y
Mol Cancer Ther; 2011 Mar; 10(3):416-26. PubMed ID: 21252288
[TBL] [Abstract][Full Text] [Related]
17. Influence of the bilayer composition on the binding and membrane disrupting effect of Polybia-MP1, an antimicrobial mastoparan peptide with leukemic T-lymphocyte cell selectivity.
dos Santos Cabrera MP; Arcisio-Miranda M; Gorjão R; Leite NB; de Souza BM; Curi R; Procopio J; Ruggiero Neto J; Palma MS
Biochemistry; 2012 Jun; 51(24):4898-908. PubMed ID: 22630563
[TBL] [Abstract][Full Text] [Related]
18. Glycan Alteration Imparts Cellular Resistance to a Membrane-Lytic Anticancer Peptide.
Ishikawa K; Medina SH; Schneider JP; Klar AJS
Cell Chem Biol; 2017 Feb; 24(2):149-158. PubMed ID: 28089756
[TBL] [Abstract][Full Text] [Related]
19. Cationic amphiphilic peptides with cancer-selective toxicity.
Schweizer F
Eur J Pharmacol; 2009 Dec; 625(1-3):190-4. PubMed ID: 19835863
[TBL] [Abstract][Full Text] [Related]
20. Selective killing of cancer cells by peptide-targeted delivery of an anti-microbial peptide.
Sioud M; Mobergslien A
Biochem Pharmacol; 2012 Nov; 84(9):1123-32. PubMed ID: 22922046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
